American BioMed Reports On Continuing Progress in Implementation of Commericalization Objectives.Business Editors THE WOODLANDS, Texas--(BUSINESS WIRE)--April 26, 2000 American BioMed, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :BB:ABMI ABMI Autologous Bone Marrow Infusion ) today announced additional milestones in commercializing its medical products. Consistent with plans to select leading distributors in international markets, the Company accepted opening orders from Scognamiglio, s.a.s. and Dong Joo Medical. Scognamiglio of Naples, Italy is a leading regional organization, offering the Company opportunity for greater sales in southern European markets. The Company's relationship with Korean distributor Dong Joo extends American BioMed's Far Eastern presence in a market of over 70 million persons. The Company also reported that, earlier in April, it successfully completed a CE mark audit of its manufacturing processes. The review was prompted by opening of a new manufacturing facility for the Company's products by MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. , supplier of American BioMed's silicone catheter products. Established by the European Community European Community: see European Union. European Community (EC) Organization formed in 1967 with the merger of the European Economic Community, European Coal and Steel Community, and European Atomic Energy Community. , the CE mark involves maintaining quality standards for safety, efficacy, and production of medical devices. American BioMed's Chairman and Interim Chief Executive Officer, Justine B. Corday, commented, "These accomplishments evidence positive steps in our dedication to transition from a developmental stage to a fully operating company operating company A business that engages in transactions with outsiders. . We will continue to devote focus to this priority, while also striving to strengthen our capital resources." American BioMed, Inc. develops, manufactures, and markets devices for minimally-invasive cardiology and other surgical procedures. This release contains forward-looking statements made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. While based on assumptions the Company believes are reasonable, actual results could differ materially based on changes in these or unforeseen factors, and the Company assumes no obligation to publicly update or revise any forward looking statements herein. Among such uncertainties are government regulation; results of research, development, and clinical testing; general economic and other market conditions; pricing and reimbursement for medical care; and market competition. Please see the Company's Securities and Exchange Commission filings for detailed discussion of such risk factors. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion